Whodrug becomes mandatory for companies to notify adverse drug events

News Healthcare & Pharma Reports

Date: 21st Mar, 2025 Source: National Health Surveillance Agency (Anvisa) Country: Brazil Original Source

Brief

On March 18, 2025, the National Health Surveillance Agency (Anvisa) published Resolution RDC nÂº 967, which updates the rules for drug pharmacovigilance. The update makes it mandatory for companies to use WHODrug (C3) for coding and E2B(R3) format for reporting adverse events through VigiMed.

This content is restricted.

Highlights content goes here...

This content is restricted.

National Health Surveillance Agency (Anvisa)

RADA.AI

Hello! I'm RADA.AI - Regulatory Analysis and Decision Assistance. Your Intelligent guide for compliance and decision-making. How can i assist you today?

Suggested

Whodrug becomes mandatory for companies to notify adverse drug events

Brief

National Health Surveillance Agency (Anvisa)

Form successfully submitted. One of our GRI rep will contact you shortly

Thanking You!

Enter your Email

Verify Email

Tell us more about yourself

Select your work area

Select your country

All set.

Whodrug becomes mandatory for companies to notify adverse drug events

Brief

National Health Surveillance Agency (Anvisa)

Form successfully submitted. One of our GRI rep will contact you shortly

Thanking You!

Enter your Email

Verify OTP

Enter your Email

Verify Email

Tell us more about yourself

Select your work area

Select your country

All set.